Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1368

1.

Use of novel oral anticoagulants for patients with atrial fibrillation: systematic review and clinical implications.

Albert NM.

Heart Lung. 2014 Jan-Feb;43(1):48-59. doi: 10.1016/j.hrtlng.2013.10.014. Epub 2013 Nov 11. Review.

PMID:
24373340
2.

Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.

Potpara TS, Polovina MM, Licina MM, Stojanovic RM, Prostran MS, Lip GY.

Adv Ther. 2012 Jun;29(6):491-507. doi: 10.1007/s12325-012-0026-8. Epub 2012 Jun 7. Review.

PMID:
22684583
3.

Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation.

Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ.

Am J Cardiol. 2012 Aug 1;110(3):453-60. doi: 10.1016/j.amjcard.2012.03.049. Epub 2012 Apr 24. Review.

PMID:
22537354
4.

An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.

Mantha S, Ansell J.

Thromb Haemost. 2012 Sep;108(3):476-84. doi: 10.1160/TH12-02-0093. Epub 2012 Jun 28. Review.

PMID:
22740145
5.

Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.

Schneeweiss S, Gagne JJ, Patrick AR, Choudhry NK, Avorn J.

Circ Cardiovasc Qual Outcomes. 2012 Jul 1;5(4):480-6. doi: 10.1161/CIRCOUTCOMES.112.965988. Epub 2012 Jul 10.

6.

A review of oral anticoagulants in patients with atrial fibrillation.

Greenspon AJ.

Postgrad Med. 2012 Nov;124(6):7-16. doi: 10.3810/pgm.2012.11.2608. Review.

PMID:
23322134
7.

Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.

Lip GY, Larsen TB, Skjøth F, Rasmussen LH.

J Am Coll Cardiol. 2012 Aug 21;60(8):738-46. doi: 10.1016/j.jacc.2012.03.019. Epub 2012 May 9.

8.

Recent advances in antithrombotic therapy for stroke prevention in patients with atrial fibrillation.

Lenchus JD.

Hosp Pract (1995). 2013 Feb;41(1):49-60. doi: 10.3810/hp.2013.02.1007.

PMID:
23466967
9.

Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.

Berman JP, Halperin JL.

Hosp Pract (1995). 2013 Feb;41(1):37-48. doi: 10.3810/hp.2013.02.1006. Review.

PMID:
23466966
10.

Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.

Cheng JW, Barillari G.

J Clin Pharm Ther. 2014 Apr;39(2):118-35. doi: 10.1111/jcpt.12122. Epub 2014 Jan 3. Review.

PMID:
24383983
11.

Novel oral anticoagulants in secondary prevention of stroke.

Diener HC, Easton JD, Hankey GJ, Hart RG.

Best Pract Res Clin Haematol. 2013 Jun;26(2):131-9. doi: 10.1016/j.beha.2013.07.007. Epub 2013 Jul 30. Review.

PMID:
23953901
12.

New anticoagulants (dabigatran, apixaban, rivaroxaban) for stroke prevention in atrial fibrillation.

Aguilar MI, Kuo RS, Freeman WD.

Neurol Clin. 2013 Aug;31(3):659-75. doi: 10.1016/j.ncl.2013.03.001. Review.

PMID:
23896498
13.

The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.

Roldán V, Marín F, Manzano-Fernández S, Gallego P, Vílchez JA, Valdés M, Vicente V, Lip GY.

J Am Coll Cardiol. 2013 Dec 10;62(23):2199-204. doi: 10.1016/j.jacc.2013.08.1623. Epub 2013 Sep 18.

14.

Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.

Harenberg J, Marx S, Diener HC, Lip GY, Marder VJ, Wehling M, Weiss C.

Int Angiol. 2012 Aug;31(4):330-9. Review.

PMID:
22801398
15.

Novel oral anticoagulants in non-valvular atrial fibrillation.

Potpara TS, Lip GY.

Best Pract Res Clin Haematol. 2013 Jun;26(2):115-29. doi: 10.1016/j.beha.2013.07.008. Epub 2013 Jul 21. Review.

PMID:
23953900
16.

Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: dawn of a new era.

Contractor T, Levin V, Martinez MW, Marchlinski FE.

Postgrad Med. 2013 Jan;125(1):34-44. doi: 10.3810/pgm.2013.01.2622. Review.

PMID:
23391669
17.

Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.

Lip GY, Kongnakorn T, Phatak H, Kuznik A, Lanitis T, Liu LZ, Iloeje U, Hernandez L, Dorian P.

Clin Ther. 2014 Feb 1;36(2):192-210.e20. doi: 10.1016/j.clinthera.2013.12.011. Epub 2014 Feb 6.

18.
19.

Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.

Assiri A, Al-Majzoub O, Kanaan AO, Donovan JL, Silva M.

Clin Ther. 2013 Jul;35(7):967-984.e2. doi: 10.1016/j.clinthera.2013.05.011.

PMID:
23870607
20.

Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.

Olesen JB, Sørensen R, Hansen ML, Lamberts M, Weeke P, Mikkelsen AP, Køber L, Gislason GH, Torp-Pedersen C, Fosbøl EL.

Europace. 2015 Feb;17(2):187-93. doi: 10.1093/europace/euu225. Epub 2014 Sep 18.

PMID:
25236181

Supplemental Content

Support Center